Innovations

MEDUWA-Vecht(e) innovations

Work package 1.1:   Watershed Information System (WIS)

Work package 1.2:    Gray Water Footprint

Work package 1.3:    Regional Risk Assessment (RRA)

Work package 1.4:    Regional Approach

Work package 2.1:    Continuous Monitoring

Work package 2.2:    Wireless Monitoring

Work package 2.3:    Nanofiltration

Work package 3:      Plasma Activated Water Oxidation

Work package 4.1:    Phytoremediation

Work package 4.2:    Herbal Antibiotic Replacement

Work package: 4.3:    Algal Antibiotic Replacement

Work package 5:      Farm Animal Monitoring

Work package 6:      Biopharmaceuticals


Innovation 1.1:   Watershed Information System (WIS)

Partners: Geoplex GIS GmbH, University of Osnabrück IUSF, Wetsus

A GIS (Geographic Information System)-supported database is being developed for the water supply, water management and decision-making authorities, the handling of pharmaceuticals and the resulting emissions of active substances into the environment for the cross-border catchment area of ​​the Vechte River (including its tributaries). The database, referred to as the Watershed Information System (WIS) is a unique and user-friendly visualization tool. In addition to pharmaceuticals, it is also used for visualizing the development and distribution of multi-resistant organisms in soil and surface waters. The WIS provides information about the quality of the entire river basin. The information system manages data from several sources gathered and generated during the project by partners and third parties. This data is combined, inter alia, with information on water use and the consumption and emission of active substances from the use of human and veterinary medicine (see WP 1.2, gray water footprint) and on the risks of emissions for ecology, human health and the economy. This is also the result of scenarios on the effects of climate change or demographic change. With all this integrated information, it is possible to simulate and visualize the effects of certain risk mitigation measures for the entire catchment area. Through the use of GIS technology, information can be identified, filtered and combined. The instrument is therefore well suited to support communication and decision-making processes associated with complex topics such as micro-contamination.


Innovation 1.2:    Gray Water Footprint

Partners: Geoplex GIS GmbH, University Twente Water Management

The aim of the app is to determine the extent of water pollution caused by the use of medicines. By spatially displaying pharmaceuticals in water, the footprint is then used to simulate the effects of the planned measures in the catchment area. The tool can also be used to evaluate and communicate existing measures.


Innovation 1.3:    Regional Risk Assessment (RRA)

Partners: AVIV BV, Radboud University Environmental Sciences

Through the spatial visualization of various risk indicators, the impact of planned management measures can be better communicated throughout the catchment area. Using computer models, previously calculated risks are translated into information formats that are suitable for informing the general public and for decision-making processes. The development of an app can also drive the user-friendliness and marketing of RRA as a separate tool.


Innovation 1.4:    Regional Approach

Partners: Waterschap Zuiderzeeland, University of Osnabrück IUSF, University Twente Water Management, Radboud University Environmental Sciences, AVIV BV

By working on: a) an inventory of the entire medical product chain, b) a cost-benefit analysis of small sewage treatment plants, and c) an analysis of the treatment performance of existing large-scale sewage treatment plants, the activities of other project partners will be supported by providing necessary background information.


Innovation 2.1:    Continuous Monitoring

Partners: InProSens, Saxion UAS, Novaris Orbit Technology BV

Development and verification of an automated, in-situ measurement system for monitoring phamaceutical concentrations and other micro-impurities in surface waters as well as effluent streams of sewage treatment plants.


Innovation 2.2:    Wireless Monitoring

Partnesr: Novaris Orbit Technology BV,  InProSens, Saxion UAS, NX Filtration, Weil Wasseraufbereitung GmbH, RUMC a.o.

The universal, wireless monitoring system is used in a variety of sensors that require numerous real-time monitoring functions. Measuring the water quality and quantity of both surface and groundwater is the case study area is further developed in the project.


Innovation 2.3:    Nanofiltration

Partners: NXFiltration BV, Weil Wasseraufbereitung GmbH, Saxion AUS

Development of processes, systems, applications and validation approaches for capillary nanofiltration involving the removal of hormone-influencing and other medicinal substances from surface water (for drinking water production and industrial water production) and effluent streams (in sewage treatment).


Innovation 3:    Plasma Activated Water Oxidation

Partners: VitalFluid, University Hospital of Münster (UKM) IfMM

The plasma reactor has a receptacle in which human excrement and urine are mixed with water to form a liquid manure. A device for separation of solid parts and fluids can be added (urine contains 75% of medicinal residues, while excrement contains only 25%). The slurry is then exposed to the plasma, which is activated in the upper part of the reactor by electrodes. In this process, air is brought into a plasma membrane, whereby more reactive oxygen and nitrogen are dissolved in a water-urine-excrement mixture. The reactive molecules oxidize antibiotics and deactivate multi-resistant microorganisms. After a pre-determined treatment time, the waste can be transferred to the conventional sewage treatment plant. An ambulatory system for patients can be connected to a toilet. In addition, the technology can be used in hospitals or as an extra cleaning step in sewage treatment plants to clean larger wastewater streams.


Innovation 4.1:    Phytoremediation

Partners: Europe Ayurveda Centrum, University Hospital of Münster (UKM) IfH and IfMM

Ayu-phytoremediation comprises of a selection of water plants for the rehabilitation of riverine and terrestrial plants for the rehabilitation of rural areas. Under the guidance of the University Hospital of Münster (UKM), a combination of terrestrial and aquatic plants are selected to provide the best results.


Innovation 4.2:    Herbal Antibiotic Replacement

Partners: Europa Ayurveda Centrum, University Hospital of Münster (UKM) IfH

Bhima choorna is a complex multi-target Ayurveda herbal preparation with an antibiotic effect and is cultivated in Overijssel. Netherlands. Bhima choorna can be processed in animal feed to increase the immune system of animals. Prophylactic use can even prevent or reduce the use of antibiotics.


Innovation 4.3:    Algal Antibiotic Replacement

Partners: Microganic GmbH,  University Hospital of Münster IfH, Wetsus a.o.

Algal Antibiotic Replacement is a powder (or paste or extract) obtained from microalgae, which has a strong antibiotic effect due to particular compounds in the algae. It can be used over the long term and prophylactically in modern livestock farming and thereby naturally increases animal welfare. It can bring the farmer the same economic benefits as the use of antibiotic performance enhancers.


Innovation 5:    Farm Animal Monitoring

Partners: Noldus Information Technology BV, Demcon BV, Ubisense GmbH

Farm animal monitoring involves the development of a non-invasive continuous monitoring for a real-time registration of animal behavior (pigs) for early detection of disease development and reduces the need for medication.


Innovation 6:    Biopharmaceuticals

Partners: Amrif, Alloksys, TDI, Phycom, Aix Scientifics

Biopharmaceutical inflammation inhibitors that can be used both for human and veterinary treatment are under development. The products b-Rescap and h-Rescap are alkaline phosphatases, with b and h referring to the corresponding protein sources. These proteins are animal (bovine) and human recombinations, which are a new class of anti-inflammatory drugs developed by the two pharmaceutical sister companies, Alloksys Life Sciences BV and AMRIF BV. These developments are intended for human medical use. However, the developers also see considerable potential of the use of the same drugs in veterinary applications, based on observations in animal tests.